Axel Grothey, MD

Articles

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

May 14th 2021

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 5th 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16th 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11th 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Grothey on the DESTINY-CRC01 Trial With Trastuzumab Deruxtecan in HER2+ CRC

December 22nd 2020

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16th 2020

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11th 2020

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Dr. Grothey on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

November 30th 2020

Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22nd 2020

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC

September 14th 2020

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

May 24th 2017

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Dr. Grothey on Treatment Landscape of mCRC

February 28th 2017

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16th 2015

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Dr. Grothey on Bevacizumab Beyond Progression in mCRC

February 22nd 2013

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.